A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

NCT06481475 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
174
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Chongqing Claruvis Pharmaceutical Co., Ltd.